Boston Scientific trades at a premium, but strong momentum in WATCHMAN, EP and MedSurg growth keeps long-term shareholders in the game despite valuation risks.

Sept 19 (Reuters) - Medical device maker Axonics has convinced a jury in California federal court that it did not violate rival Medtronic's (MDT.N), opens new tab patent rights in nerve-stimulation ...

Boston Scientific’s proposed $3.7 billion acquisition of medical device maker Axonics Inc. will likely be scrutinized by the US Federal Trade Commission because the companies are the dominant ...

A 41-year-old nurse from Severance shopping for a solution to her overactive bladder symptoms found a way to regain full control thanks to an innovative procedure. Sarah Avrech said goodbye to a life ...

Medtronic is going after Axonics once again, this time with accusations that its competitor in sacral neuromodulation is illegally using Medtronic’s MRI compatibility technology. The accusations come ...

Medtronic is upping the ante in a patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic’s InterStim device, an implanted ...

Medical device giant Boston Scientific announced a $3.7 billion deal on Monday to augment its urology portfolio. The company is acquiring Axonics, a maker of neurostimulation devices that treat ...

Boston Scientific will acquire Axonics for about $3.7 billion in cash. The companies said on Monday that Axonics had agreed to be bought for $71 a share. Boston Scientific said the deal gave Axonics ...

Boston Scientific Corporation (NYSE:BSX) has agreed to acquire Axonics Inc (NASDAQ: AXNX) for $71 in cash per share, representing an enterprise value of approximately $3.4 billion and an equity value ...